MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Altimmune Inc

Aperta

4.01 4.7

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.84

Massimo

4.05

Metriche Chiave

By Trading Economics

Entrata

-2.6M

-22M

Vendite

5K

Margine di Profitto

-442,920

Dipendenti

59

EBITDA

-2.7M

-23M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+385.79% upside

Dividendi

By Dow Jones

Utili prossimi

11 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

79M

353M

Apertura precedente

-0.69

Chiusura precedente

4.01

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Altimmune Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 ott 2025, 23:30 UTC

Azioni calde

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 ott 2025, 21:21 UTC

Utili

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 ott 2025, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 ott 2025, 23:40 UTC

Discorsi di Mercato

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 ott 2025, 23:39 UTC

Discorsi di Mercato

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 ott 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 ott 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 ott 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 ott 2025, 23:00 UTC

Discorsi di Mercato

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 ott 2025, 22:54 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Scales's JV Buyout Lauded by Bull -- Market Talk

2 ott 2025, 22:54 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Forex and Fixed Income Roundup: Market Talk

2 ott 2025, 22:46 UTC

Discorsi di Mercato

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 ott 2025, 22:46 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

2 ott 2025, 21:17 UTC

Acquisizioni, Fusioni, Takeovers

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 ott 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Energy & Utilities Roundup: Market Talk

2 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

2 ott 2025, 20:49 UTC

Acquisizioni, Fusioni, Takeovers

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 ott 2025, 20:00 UTC

Acquisizioni, Fusioni, Takeovers

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 ott 2025, 19:20 UTC

Discorsi di Mercato

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 ott 2025, 19:10 UTC

Discorsi di Mercato

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 ott 2025, 19:04 UTC

Discorsi di Mercato

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 ott 2025, 18:46 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 ott 2025, 18:46 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 ott 2025, 18:46 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 ott 2025, 18:45 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 ott 2025, 18:45 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 ott 2025, 18:44 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 ott 2025, 18:44 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 ott 2025, 18:44 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 ott 2025, 18:43 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Confronto tra pari

Modifica del prezzo

Altimmune Inc Previsione

Obiettivo di Prezzo

By TipRanks

385.79% in crescita

Previsioni per 12 mesi

Media 18.8 USD  385.79%

Alto 25 USD

Basso 12 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Altimmune Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

5

Acquista

1

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

5.365 / 6.0486Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
help-icon Live chat